Insider buying last 90 days
No open-market insider purchases were filed for PRGO in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every PRGO insider filing, plotted on the chart in Gekko.Open PRGO in Gekko
NYSE: PRGO
Perrigo (PRGO) Stock Analysis & Forecast
Oct 12 close
$15.45+0.39 (+2.6%)
Gekko Brief
AI summaryOct 12 closePerrigo shares have been climbing on speculation and valuation chatter rather than company-specific operating news. Reports cited by Betaville suggest Perrigo may have attracted takeover interest, with speculation naming CVC Capital as a possible buyer looking to merge it with Cooper Consumer Health. Separately, commentary around InvestingPro's Fair Value models and a GF Score of 60/100 has highlighted the stock as undervalued, accompanying a run from roughly $9.53 in March 2026 to recent levels near $15.42 and $15.06.
Perrigo closed at $15.45, up 2.6%, sitting above both its 50-day average of $13.89 and 200-day average of $12.33, with the 50-day above the 200-day. The GekkoIndex reads 51.9, placing it in the Neutral zone, down 4.3 points over five sessions. Against a Gekko Fair Value of $25.48, the current price sits 39.4% below that level.
Perrigo's next earnings report is set for 4 November 2026, before the open, 22 days out and within a typical 20-trading-day holding window; its last report showed EPS of $0.77 versus a $0.80 estimate, with an 8.3% reaction. No insider, Congress or unusual options activity appears in the current windows. Seasonality over the next 20 trading days has averaged -2.7% across 5 years, rising in 3 of them, a pattern worth noting given the proximity of earnings.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Perrigo price vs fair value
Close $15.45200-day averageGekko Fair Value $25.48
Perrigo quick facts
- Market cap
- $2.14B
- P/E ratio
- —
- Forward P/E
- 6
- EPS, TTM
- −$12.28
- Revenue, TTM
- $4.14B
- Profit margin
- -41.8%
- Dividend yield
- 7.97%
- Beta
- 0.69
- Volume
- 1.84M avg 2.93M
- 1-year return
- −28.3%
- Typical daily move
- ±4.9%
- Typical 20-day move
- ±5.9%
- 50-day average
- $13.89
- 200-day average
- $12.33
- Next earnings
- Nov 4 before open
- Shares outstanding
- 138.4M
Perrigo swing-trade checklist
Perrigo scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $15.45 is above the 50-day ($13.89) and 200-day ($12.33) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
51.9, Neutral
Reading 51.9 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
39.4% below
Price is 39.4% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
−2.7% on average
From this point in the calendar, the next 20 trading days averaged −2.7% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Perrigo stock chart and price history
Perrigo closed at $15.45 on Oct 12, 2026, −28.3% over the past year, inside a 52-week range of $9.23 to $22.02.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +13.1%
- 3 months
- +56.1%
- 6 months
- +36.6%
- 1 year
- −28.3%
The full PRGO chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PRGO in Gekko
Follow Perrigo through every session
Put PRGO on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track PRGO in GekkoFree for 7 days. No credit card required.
About Perrigo
Perrigo makes everyday over-the-counter health and wellness products sold to consumers in the United States, Europe, and other markets. Its range spans cough and sinus remedies, infant formula and electrolyte drinks, digestive aids, pain relievers, oral care items such as toothbrushes and whitening products, skin care treatments, smoking cessation aids, feminine hygiene and contraceptive products, and vitamins and supplements. These goods reach shoppers under a wide set of brand names, including Compeed, Mederma, Nasonex, Plackers, Opill, Solpadeine, and ellaOne, among others.
The business is split into two segments, Consumer Self-Care Americas and Consumer Self-Care International, reflecting its geographic reach beyond North America. Alongside its own branded lines, it also provides contract manufacturing for other companies. Products move to consumers through retail drugstores, supermarkets, mass merchandise chains, wholesalers, pharmacies, grocery retailers, para-pharmacies, and e-commerce channels.
Perrigo traces its history back to 1887 and operated for years under the name Perrigo Company before adopting its current name, Perrigo Company plc, in December 2013. It is headquartered in Dublin, Ireland, and its shares are listed on the NYSE under the ticker PRGO.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- perrigo.com
Perrigo GekkoIndex: the smart money zone
Perrigo’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.9, in the Neutral zone, down 4.3 points over five sessions.
51.9Neutral
Down 4.3 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 78 | −0.9% | −0.4% | ||
| Accumulation | 242 | −0.4% | −0.6% | ||
| Neutral (current zone) | 352 | −0.2% | −2.6% | ||
| Distribution | 9 | Too few readings yet | |||
| Selling | 1 | Too few readings yet | |||
Average PRGO share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the PRGO price, zone by zone.Track PRGO in Gekko
Is Perrigo stock overvalued? Gekko Fair Value
Perrigo trades 39.4% below Gekko Fair Value of $25.48, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Perrigo shares are worth, recalculated every trading day.
$25.48
Gekko Fair Value, Oct 10, 2026
39.4% Undervalued
At the end of Aug 2026 the price was 0.9% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open PRGO in Gekko
Perrigo insider and Congress trading
No open-market insider purchases were filed for Perrigo, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in PRGO were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for PRGO, plotted on the chart in Gekko.Open PRGO in Gekko
Buybacks
Perrigo has been buying back its own shares.
- Bought back, year ended Dec 31, 2020
- $164.2M
- As a share of market cap
- 7.68%
From company filings.
Hedge funds and billionaires quarter ended Sep 30
0of the funds Gekko tracks hold PRGO.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Perrigo earnings: next date and track record
Perrigo reports on Nov 4, 2026, before the open (23 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected before the open, 23 days away
- EPS estimate
- $0.52
- Revenue estimate
- $991.5M
4 of 8reports beat the EPS estimate
±10%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Feb 26, 2026 AI summary
- What they said
- Perrigo reported full-year 2025 results, emphasizing progress on a multi-year transformation (Three-S Plan) with share gains across U.S. OTC and European markets, improved in-store execution, and EPS in line with revised guidance. Management introduced a CORE reporting concept excluding certain divestitures and outlined a transition to new reporting segments in 2026. However, GAAP results included a $1.3 billion noncash goodwill impairment and management disclosed potential additional noncash impairments up to $350 million in Q1 2026. Management described 2026 as a transitory year due to soft OTC consumption, inventory-driven under-absorption (approximately $0.60 impact), and continued structural challenges in the Infant Formula business, which is under strategic review. The company plans an operational enhancement program to address margin under-absorption and expects market normalization and most improvement to occur in the second half of 2026. Capital allocation priorities remain investing in the business, reducing leverage (using expected Dermacosmetics proceeds in early Q2 to pay down debt), and returning value via dividends (dividend maintained). Management reiterated long-term leverage goal (previously below 3x by 2027) but now expects to reach that in roughly 2–3 years given transitory headwinds.
- Guidance
- 2026 characterized as a transitory year with expected market improvement in H2 2026. Management expects continued share gains, store-brand OTC growth, and that ~60–65% of innovation, geographic expansion, and distribution gains land in H2. Infant Formula: company expects low- to mid-single-digit revenue growth in 2026 (to help deplete inventory and restore gross profit). Financial: adjusted net leverage expected to be in line with or slightly better than 2025 for 2026, and achieving <3x leverage anticipated over the next 2–3 years (delayed from prior expectation). Potential additional noncash goodwill impairment charges up to $350 million may be recorded in Q1 2026. Dermacosmetics sale expected to close early Q2 2026 with proceeds to reduce debt. No specific dollar revenue or EPS targets were provided on the call.
- Risks flagged
- Large noncash goodwill impairment already recorded ($1.3B) and potential additional impairments (up to $350M) in Q1 2026; structural challenges and cash consumption in the Infant Formula business with strategic review outcomes uncertain; elevated inventories and working capital pressures, leading to under-absorption and margin pressure in 2026; soft OTC market and category-specific declines (notably cough/cold and certain pain pill subsegments); competitive commoditization in CSCI molecules; timing risk tied to Dermacosmetics sale closure and recovery assumptions; macro/retail dynamics affecting pricing and household consumption.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Feb 26, 2026 | $0.77 est $0.80 | $1.11B est $1.10B | −8.3% |
| Nov 5, 2025 | $0.80 est $0.75 | $1.04B est $1.09B | −26.1% |
| Aug 6, 2025 | $0.57 est $0.59 | $1.06B est $1.10B | −14.2% |
| May 2, 2025 | $0.60 est $0.57 | $1.04B est $1.08B | −0.1% |
| Feb 27, 2025 | $0.36 est $0.95 | $1.14B est $1.09B | +16.5% |
| Nov 6, 2024 | $0.81 est $0.83 | $1.09B est $1.20B | +6.2% |
| Aug 2, 2024 | $0.53 est $0.46 | $1.07B est $1.13B | +1.8% |
| May 7, 2024 | $0.29 est $0.23 | $1.08B est $1.09B | −6.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Perrigo stock forecast and analyst price targets
Analysts’ average 12-month price target for Perrigo is $16.50, +6.8% from the last close, from 1 firm rating the stock in the last 90 days.
$16.50consensus 12-month target, +6.8% from the last close
Each firm’s latest rating in the last 90 days: 1 firm.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 6 | Canaccord Genuity | $17 | +10.0% |
−2.6%average 20-day move after past Neutral readings
−2.7%average move over the next 20 trading days in the last 5 years
±4.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Perrigo seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Perrigo averaged −2.7% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.1% | 4 of 5 |
| Next 10 trading days | +1.6% | 3 of 5 |
| Next 15 trading days | +0.2% | 3 of 5 |
| Next 20 trading days | −2.7% | 3 of 5 |
| Next 30 trading days | −11.8% | 1 of 5 |
For scale, PRGO’s typical 20-trading-day move in either direction is about 5.9%.
Perrigo market cap and key statistics
Perrigo’s market cap is $2.14B and revenue of $4.14B over the last twelve months.
Valuation
- Market cap
- $2.14B
- Forward P/E
- 6
- EPS, TTM
- −$12.28
- Gekko Fair Value
- $25.48
Trading
- Volume
- 1.84M
- Avg volume, 20 days
- 2.93M
- 52-week high
- $22.02
- 52-week low
- $9.23
- Shares outstanding
- 138.4M
Financials
- Revenue, TTM
- $4.14B
- Profit margin
- -41.8%
- Return on equity
- -48.7%
- Quarterly earnings growth, YoY
- −63.6%
Risk and income
- Beta
- 0.69
- Typical daily move
- ±4.9%
- Typical 20-day move
- ±5.9%
- Dividend yield
- 7.97%
Perrigo stock news this week
Coverage of Perrigo this week reads positive: 3 positive, 0 neutral and 0 negative headlines.
- Perrigo Co PLC (PRGO) Stock Up 3.9% and Still Undervalued -- GF Score: 60/100GuruFocus, Oct 9
- Perrigo may have attracted takeover interest - BetavilleSeeking Alpha, Oct 9
- Perrigo Company plc $PRGO Shares Bought by O Keefe Stevens Advisory Inc.MarketBeat, Oct 9
- Perrigo stock soars 62% after InvestingPro Fair Value call By Investing.comInvesting.com, Oct 5
Perrigo peers
Perrigo’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Perrigo stock FAQ
What is Perrigo’s market cap?
Perrigo’s market cap is $2.14B at the Oct 12, 2026 close of $15.45, with 138.4M shares outstanding.
What is the Perrigo stock forecast?
The consensus analyst 12-month price target for Perrigo is $16.50, +6.8% from the last close. Of the 1 firm that rated the stock in the last 90 days, 1 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Perrigo stock overvalued or undervalued?
On Gekko’s estimate Perrigo is undervalued: the Oct 12, 2026 close of $15.45 is 39.4% below Gekko Fair Value of $25.48. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Perrigo report earnings next?
Perrigo is expected to report on Nov 4, 2026, before the market opens (23 days away). Analysts expect earnings of $0.52 per share on revenue of $991.5M. Perrigo beat the earnings estimate in 4 of its last 8 reports, moving 10% on average across the report.
What is Perrigo’s 52-week high and low?
Perrigo’s 52-week high is $22.02 and its 52-week low is $9.23; it closed at $15.45 on Oct 12, 2026, −28.3% over the past year. Over the last five years the shares peaked at $47.95 on Nov 8, 2021.
Is Perrigo stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and fair value), 2 as mixed (gekkoindex and seasonality) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Perrigo the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.